Dose-escaltion in head and neck cancer A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach

Radiotherapy and Oncology

Volumn 106, Issue 3, 2013, Pages 333-340

  Leclerc, Mathieu ^a   Maingon, Philippe ^b   Hamoir, Marc ^a   Dalban, Cécile ^b   Calais, Gilles ^c   Nuyts, Sandra ^d   Serre, Antoine ^e   Grégoire, Vincent ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d Katholieke Universiteit   (Belgium)

^e CENTRE VAL D AURELLE   (France)

Author keywords

Head and neck carcinoma IMRT Simultaneous integrated boost Dose escalation

Indexed keywords

ADULT; ARTICLE; CANCER CONTROL; CANCER LOCALIZATION; CANCER PATIENT; CANCER PREVENTION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; HYPOPHARYNX CARCINOMA; HYPOPHARYNX SQUAMOUS CELL CARCINOMA; INTENSITY MODULATED RADIATION THERAPY; LARYNX SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; OROPHARYNX CARCINOMA; OROPHARYNX SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLANNING TARGET VOLUME; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIATION HAZARD; SIMULTANEOUS INTEGRATED BOOST TECHNIQUE; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; CANCER STAGING; HYPOPHARYNX TUMOR; LARYNX TUMOR; METHODOLOGY; MIDDLE AGED; OROPHARYNX TUMOR; PATHOLOGY;

CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84876100268     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.03.002     Document Type: Article

References (34)

1. M. Yao, M. Lu, and P. Savvides Distant metastases in head-and-neck squamous cell carcinoma treated with intensity-modulated radiotherapy Int J Radiat Oncol Biol Phys 83 2012 684 689
2. M.O. Al-Othman, C.G. Morris, R.W. Hinerman, R.J. Amdur, and W.M. Mendenhall Head Neck 25 2003 629 633
3. J. Bourhis, J. Overgaard, and H. Audry Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis Lancet 368 2006 843 854
4. K.K. Fu, T.F. Pajak, and A. Trotti A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 Int J Radiat Oncol Biol Phys 48 2000 7 16
5. J.C. Horiot, R. LeFur, and T. N'Guyen Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy Radiother Oncol 25 1992 231 241
6. J.C. Horiot, P. Bontemps, and W. Van Den Bogaert Accelerated fractionation compared to conventional fractionation improves locoregional control in the radiotherapy of advanced head and neck cancer: results of the EORTC 22581 randomized trial Radiother Oncol 44 1997 111 121
7. J. Overgaard, H.S. Hansen, and L. Specht Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial Lancet 362 2003 933 940
8. J. Bourhis, M. Lapeyre, and J. Tortochaux Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial J Clin Oncol 24 2006 2873 2878
9. E.B. Butler, B.S. Teh, and W.H. Grant Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy Int J Radiat Oncol Biol Phys 45 1999 21 32
10. R. Mohan, Q. Wu, M. Manning, and R. Schmidt-Ullrich Radiobiological considerations in the design of fractionation strategies fir intensity-modulated radiation therapy of head and neck cancers Int J Radiat Oncol Biol Phys 46 2000 619 630
11. National Cancer Institute. Common toxicity criteria (CTC) v2.0. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc. htm. Accessed August 2012.
12. RTOG. RTOG/EORTC late radiation morbidity scoring schema. Available from: http://www.rtog.org/ResearchAssociates/AdverseEventReporting/ RTOGEORTCLateRadiationMorbidityScoringSchema.aspx. Accessed August 2012.
13. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v4.0. Available from: http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/ctc.htm. Accessed August 2012.
14. S. Marcié, P. Aletti, D. Lefkopoulos, and M. Tomsej Quality assurance program for intensity-modulated radiotherapy (IMRT) treatments of head and neck carcinomas Cancer Radiother 7 2003 172 178
15. V. Gregoire, E. Coche, and G. Cosnard Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience Radiother Oncol 56 2000 135 150
16. V. Gregoire, A. Eisbruch, and M. Hamoir Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck Radiother Oncol 79 2006 15 20
17. Prescribing, recording and reporting photon beam therapy. International Commission on Radiation Units and Measurements, report 50, 1993.
18. Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). International Commission on Radiation Units and Measurements, report 62, 1999.
19. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
20. J.P. Pignon, J. Bourhis, C. Domenge, and L. Designé Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. meta-analysis of chemotherapy on head and neck cancer Lancet 355 2000 949 955
21. J.P. Pignon, A. le Maître, E. Maillard, and J. Bourhis MACH-NC collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients Radiother Oncol 92 2009 4 14
22. P. Blanchard, B. Baujat, and V. Holostenco Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site: MACH-CH collaborative group Radiother Oncol 100 2011 33 40
23. J. Bourhis, C. Sire, and P. Graff Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial Lancet Oncol 13 2012 145 153
24. G.H. Fletcher Hypofractionation: lessons from complications Radiother Oncol 20 1991 10 15
25. H.R. Mortensen, J. Overgaard, and L. Specht Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer Radiother Oncol 103 2012 69 75
26. A. Trotti, L.A. Bellm, and J.B. Epstein Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radioherapy with or without chemotherapy: a systematic literature review Radiother Oncol 66 2003 253 262
27. T.G. Wendt, G.G. Grabenbauer, C.M. Rödel, H.J. Thiel, H. Aydin, and R. Rohloff Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study J Clin Oncol 16 1998 1318 1324
28. A. Lauve, M. Morris, and R. Schmidt-Ullrich Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II - clinical results Int J Radiat Oncol Biol Phys 60 2004 374 387
29. M. Machtay, J. Moughan, and A. Trotti Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis J Clin Oncol 26 2008 3582 3589
30. F. Denis, P. Garaud, and E. Bardet Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems Int J Radiat Oncol Biol Phys 55 2003 93 98
31. P. Ghadjar, M. Simcock, and F. Zimmermann Predictors of severe late radiotherapy related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94) Radiother Oncol 104 2012 213 218
32. E. Eisbruch, J. Harris, and A.S. Garden Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22) Int J Radiat Oncol Biol Phys 76 2010 1333 1338
33. P. Lassen, J.G. Eriksen, and A. Krogdahl The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial Radiother Oncol 100 2011 49 55
34. I. Madani, F. Duprez, and T. Boterberg Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer Radiother Oncol 101 2011 351 355